Biotech · Public company · New Haven, CT, US

Arvinas, Inc.

Ticker ARVN · SEC CIK 0001655759

Track this companyFree. Adds Arvinas, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials53 recruiting or active

Pipeline programs10From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline10

AnastrozolePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ARV-110Phase 2 · Prostate Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
ARV-471Phase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ARV-6723Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
ARV-806Phase 2 · KRAS G12D MutationClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
SOCPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Surgical resection of breast tumorPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ARV-393Phase 1 · Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)ClinicalTrials.gov · fetched Nov 12, 2026
GlofitamabPhase 1 · Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)ClinicalTrials.gov · fetched Nov 12, 2026

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Jul 29, 2026ClinicalTrials.gov NCT07749586 · fetched Nov 12, 2026
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 29, 2025ClinicalTrials.gov NCT07023731 · fetched Nov 12, 2026
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.PHASE1 · RECRUITING · started Sep 5, 2024ClinicalTrials.gov NCT06393738 · fetched Nov 12, 2026
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryPHASE2 · COMPLETED · started Feb 15, 2023ClinicalTrials.gov NCT05549505 · fetched Nov 12, 2026
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate CancerPHASE1_PHASE2 · COMPLETED · started Mar 1, 2019ClinicalTrials.gov NCT03888612 · fetched Nov 12, 2026